ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Achillion Pharmaceuticals Inc

Achillion Pharmaceuticals Inc (ACHN)

6,76
0,00
(0,00%)
Beim Schlusskurs: 25 November 10:00PM
6,76
0,00
( 0,00% )
Nach Börsenschluss: -

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
6,76
Gebot
6,93
Fragen
6,75
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Handelsende
6,76
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
-
Durchschnittliches Volumen (3 Mio.)
-
Finanzvolumen
-
VWAP
-

ACHN Neueste Nachrichten

Achillion Shareholders Approve Agreement to be Acquired by Alexion

BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who...

– 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –- Completed End of Phase 2 Meeting; Phase 3 Trial...

Moore Kuehn, PLLC Encourages Investors of SRC Energy, Inc. (SRCI), Achillion Pharmaceuticals, Inc. (ACHN), and Arotech Corpor...

Moore Kuehn, PLLC Encourages Investors of SRC Energy, Inc. (SRCI), Achillion Pharmaceuticals, Inc. (ACHN), and Arotech Corporation (ARTX) to Contact Firm PR Newswire NEW YORK, Nov. 22, 2019 NEW...

European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients...

BLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update

– Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase...

Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting

BLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc. PR Newswire NEW YORK, Oct. 18, 2019 NEW YORK, Oct. 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible...

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Achillion Pharmaceuticals, Inc. has obtained a Fair Price in it...

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Achillion Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Alexion Pharmaceuticals, Inc. PR Newswire MILWAUKEE...

Achillion (ACHN) Alert: Johnson Fistel Investigates Proposed Sale of Achillion Pharmaceuticals; Are Shareholders Getting a Fa...

Achillion (ACHN) Alert: Johnson Fistel Investigates Proposed Sale of Achillion Pharmaceuticals; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, Oct. 16, 2019 SAN DIEGO, Oct. 16, 2019...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
XCURExicure Inc
US$ 25,80
(40,37%)
316,86k
BFRIBiofrontera Inc
US$ 1,09
(25,29%)
8,74M
GTRWisdomTree Target Range Fund
US$ 30,00
(19,52%)
1,35k
QMCOQuantum Corporation
US$ 10,88
(19,17%)
1,24M
VEROVenus Concept Inc
US$ 0,3698
(13,78%)
4,32M
KALAKALA BIO Inc
US$ 5,59
(-17,73%)
1,63k
NIVFNewGenIvf Group Ltd
US$ 0,4274
(-16,03%)
303,53k
SLXNSilexion Therapeutics Corporation
US$ 0,26
(-15,31%)
178,3k
AKTSAkoustis Technologies Inc
US$ 0,0854
(-15,11%)
3,6M
ELABElevai Labs Inc
US$ 0,0174
(-13,43%)
69,46M
PARAParamount Global
US$ 11,20
(0,72%)
3,37M
TLTiShares 20 plus Year Treasury Bond
US$ 92,66
(-0,03%)
1,81M
NVDANVIDIA Corporation
US$ 136,38
(0,32%)
1,06M
NTNXNutanix Inc
US$ 72,80
(-0,12%)
915,43k
TSLATesla Inc
US$ 336,46
(-0,59%)
903,62k
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock